Former Aptose director exits stake in Hammi deal
Former Aptose Biosciences director Warren Whitehead disposed of all his remaining interests in the company on June 30, 2026 as part of a business arrangement under which Hammi Pharmaceuticals acquired all outstanding Aptose shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Former Aptose Biosciences director Warren Whitehead disposed of all his remaining interests in the company on June 30, 2026 as part of a business arrangement under which Hammi Pharmaceuticals acquired all outstanding Aptose shares. He returned 33 common shares at about $1.72 per share and multiple director stock options to the issuer, leaving him with no direct Aptose shares or options after the transactions.
Insider Trade Summary
Disposition: 548,866 shares
Disposition
10 txns
Insider
Whitehead Warren
Role
Insider
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Director Stock Option (Right to Buy) | 3,333 | $0.00 | $0.00 |
| Disposition | Director Option Grant | 100,000 | $0.00 | $0.00 |
| Disposition | Director Option Grant | 50,000 | $0.00 | $0.00 |
| Disposition | Director Option Grant | 50,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
| Disposition | Director Option Grant | 50,000 | $0.00 | $0.00 |
| Disposition | Director Option Grant | 152,500 | $0.00 | $0.00 |
| Disposition | Stock Options (Right to Buy) | 40,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 53,000 | $0.00 | $0.00 |
| Disposition | Common Shares | 33 | $1.72 | $56.76 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 0 contracts (Direct);
Director Option Grant — 0 contracts (Direct);
Stock Options (Right to Buy) — 0 contracts (Direct);
Common Shares — 0 shares (Direct)
Footnotes (3)
- F1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
- F2. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
- F3. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
Key Figures
Common shares disposed: 33 shares
US dollar share value: $1.72 per share
Canadian consideration price: C$2.41 per share
+5 more
8 metrics
Common shares disposed
33 shares
Returned to issuer on June 30, 2026
US dollar share value
$1.72 per share
Converted from C$2.41 at C$1.4=US$1.00
Canadian consideration price
C$2.41 per share
Hammi acquisition price for outstanding Aptose shares
Options disposed at $3.52
53,000 options
Director stock options with $3.52 exercise price
Options disposed at $1.91
40,000 options
Stock options with $1.91 exercise price
Largest option block disposed
152,500 options
Director option grant with $6.91 exercise price
Low-strike option block
100,000 options
Director option grant with $0.66 exercise price
Post-transaction holdings
0 shares/options
Total direct Aptose holdings after reported dispositions
Key Terms
Disposition to issuer, business arrangement agreement, director stock option, option grant, +2 more
6 terms
Disposition to issuer financial
"transaction_action: issuer disposition"
business arrangement agreement financial
"Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement"
director stock option financial
"Director Stock Option (Right to Buy)"
option grant financial
"Director Option Grant"
exchange rate financial
"using an exchange rate of C$1.4 = US$1.00"
Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.
Hammi Pharmaceuticals Co. Ltd. financial
"between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Warren Whitehead report in his Aptose Biosciences (APTOF) Form 4?
Warren Whitehead reported disposing of all his remaining Aptose Biosciences holdings. He returned 33 common shares and multiple director stock options to the issuer, leaving him with zero direct Aptose shares or options following the transactions.
What happened to Warren Whitehead’s Aptose Biosciences (APTOF) stock options?
Whitehead reported the disposition of several blocks of director stock options back to the issuer, covering tens of thousands of underlying common shares at exercise prices ranging from $0.66 to $6.91, leaving no remaining reported options after the transaction.
Does Warren Whitehead still hold any Aptose Biosciences (APTOF) securities after these transactions?
No. The Form 4 shows total shares following each transaction as zero for both common shares and the reported stock options, indicating he no longer holds direct Aptose Biosciences equity or related option positions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates